Charles & Colvard Announces Strategic Shift Within Its Traditional Business Segment; Launches Charlesandcolvarddirect.com

 Charles & Colvard, Ltd. (NASDAQ:CTHR) (the "Company"), a globally recognized fine jewelry company specializing in lab-created Made, Not Mined™ gems, is proud to unveil its new digital B2B trade-portal,

 Charles & Colvard, Ltd. (NASDAQ:CTHR) (the “Company”), a globally recognized fine jewelry company specializing in lab-created Made, Not Mined™ gems, is proud to unveil its new digital B2B trade-portal, charlesandcolvarddirect.com. This portal will support the Company’s significant shift away from its current distributor model, creating a pathway for tens of thousands of independent jewelers and retailers to purchase its loose gems directly from the Company for the first time in its nearly three-decade history.

“We are excited to formally announce the launch of Charles & Colvard Direct, which, we believe, will be a catalyst for future growth based on this significant shift in our Company’s traditional business model,” said Don O’Connell, President and CEO of Charles & Colvard.

Approved Charles & Colvard Direct retailers and independent jewelers can now browse and purchase the full catalog of Charles & Colvard’s premium brand of moissanite gems, Forever One™, along with the Company’s newest gemstone brand, Forever Bright™ moissanite, on the self-service portal.

“We understand the challenges faced by independent jewelers and retailers to remain competitive in the face of downward pricing pressure on gems in the current environment,” said O’Connell. “By cutting out the middleman and selling directly to these businesses, we can offer better prices on our gems, supporting the independents and maintaining brand integrity in a market saturated with misinformation, false grading claims and counterfeit moissanite,” O’Connell concluded.

Forever Bright™ will replace Moissanite by Charles & Colvard® as the Company’s offering for the price-conscious consumer. While generally invisible to the naked eye, magnifying these gems may reveal ever-slight cut, clarity, or polish imperfections. Forever Bright™ competes with the cost of foreign-developed moissanite while maintaining exceptional quality standards synonymous with the Charles & Colvard brand.  To learn more about Charles & Colvard Direct visit www.charlesandcolvarddirect.com.

Total
0
Shares
Related Posts
Read More

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer

Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold as part of a profit-sharing agreement with Incyte, which saw net product sales of $92 million in 2023. MorphoSys also is developing Pelabresib, an inhibitor of proteins involved in the development and progression of myelofibrosis.

INCY